Experimental small molecule that stimulates hippocampal neurogenesis. Developed for major depressive disorder, it promotes the growth of new neurons in the hippocampus, the brain region critical for memory and mood.
Neural Network
Nootropic peptides enhance synaptic plasticity and neurotransmitter release.
Quickstart Highlights
- Dosage: 10-40mg
- Frequency: 1-2x daily (oral)
- Administration: Oral
- Cycle length: 8-12 weeks
How This Works
Mechanism of Action
How NSI-189 Works in Your Body
Peptide Administered
Crosses the blood-brain barrier
Neurotransmitter Boost
Enhances BDNF and neurotrophic factors
Synaptic Activity
Neurons fire more efficiently, forming new connections
Focus & Memory
Improved clarity, recall, and cognitive performance
Benefits & Side Effects
Potential Benefits
- Neurogenesis
- Cognitive enhancement
- Mood improvement
- Hippocampal growth
Quick notes
Limited human data. Investigational. Not approved for clinical use.
References
Community Insights
Summarised from 1 sourceExperimental small molecule that stimulates hippocampal neurogenesis. Developed for major depressive disorder, it promotes the growth of new neurons in the hippocampus, the brain region critical for memory and mood. Limited human data. Investigational. Not approved for clinical use.
Common Dosages Reported
- 10-40mg 1-2x daily (oral)
- Standard protocol dosing
Side Effects Mentioned
- Generally mild, individual variation expected
- See full guide for detailed safety info
Stacking Suggestions
- Consult research and healthcare provider before stacking
What people are saying
Results vary based on individual response
Consistent dosing and timing important
Reviews & Discussion
Real experiences shared by the community — not medical advice.
Improved Spatial Memory and Emotional Processing
A user reported that NSI-189 significantly improved their spatial memory, navigation, and sense of direction. They also noted enhanced emotional processing and a decrease in depressive symptoms, although they experienced minor physical side effects like tingling sensations.
Reduction in Brain Fog and Lasting Cognitive Clarity
One individual described a profound reduction in "brain fog" and a return of cognitive clarity after using NSI-189. They mentioned that the effects felt long-lasting even after they stopped the daily dosage.
Increased Irritability and Emotional Volatility
A user experienced intense emotional volatility and irritability while taking NSI-189. While they felt more "awake," the frequent mood swings and heightened anxiety made the experience difficult to manage.
Synergy with Tianeptine for Mood and Fluency
A user found that combining NSI-189 with Tianeptine produced a synergistic effect that improved their mood more than either substance alone. They noted a significant reduction in social anxiety and improved verbal fluency with this combination.
Stimulant Sensitivity Increase
A report mentions that combining NSI-189 with stimulants like caffeine or methylphenidate can lead to over-stimulation. The user reported feeling jittery and over-focused, suggesting that NSI-189 might lower the threshold for stimulant sensitivity.
No Effects After 15 Days of Sublingual Use
A user reported using NSI-189 in freebase form at 20mg sublingually for 15 days. They noted that they have experienced no effects and have noticed nothing from the compound during this time.
Reported Emotional and Cognitive Improvements
A user shared second-hand observations from another individual using 40mg daily, reporting that effects become noticeable after a few days. The reported benefits included deeper emotions, the elimination of depressed states, an elevated ability to handle stress, and improved memory, including the retrieval of lost memories.
My experience with NSI-189
A user shared their experience with NSI-189 within a broader discussion about RAD-140 and dosing schedules. While the specific details of the effects were not elaborated upon in the snippet, the report was presented as a dedicated account of their personal results with the compound.
Dosage and Time of Action Observations
A user noted that in clinical contexts for depression, NSI-189 reportedly began showing effects around day 18 for those taking 120mg daily, while a 40mg daily dose was found to be the most effective by day 23.
Clinical Trial Failure Report
Recent reports highlight that NSI-189 (ALTO-100) failed to meet its primary endpoints in Phase 2b clinical trials. The substance did not significantly outperform a placebo in the treatment of major depressive disorder.
NSI-189 for Treatment Resistant Depression/Anxiety
A user considering NSI-189 for treatment-resistant depression and historical neurological damage noted that they felt more like their 'old self' while using it. They described the effect as subtle yet effective for emotional processing, though they cautioned that it can cause increased irritability in some individuals.
No discussion yet — be the first.
No notes yet — be the first.